Does CDX2 expression predict Barrett's metaplasia in oesophageal columnar epithelium without goblet cells?

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 11-12, 2006, Pages 1613-1621

  Kerkhof, M ^a   Bax, D A ^a   Moons, L M G ^a   Van Vuuren, A J ^a   Van Dekken, H ^a   Steyerberg, E W ^a   Kuipers, E J ^a   Kusters, J G ^a   Siersema, P D ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MUCIN 2; TRANSCRIPTION FACTOR CDX2; VILLIN;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; COLUMNAR EPITHELIUM; CONTROLLED STUDY; ESOPHAGUS BIOPSY; FOLLOW UP; GOBLET CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; BIOLOGICAL MARKERS; BIOPSY; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGUS; GOBLET CELLS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; METAPLASIA; MIDDLE AGED;

EID: 33845512531     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03163.x     Document Type: Article

References (37)

1. Avidan B, Sonnenberg A, Schnell TG, et al. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002; 97: 1930-6.
2. Buttar NS, Wang KK. Mechanisms of disease: carcinogenesis in Barrett's esophagus. Nat Clin Pract Gastroenterol Hepatol 2004; 1: 106-12.
3. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994; 25: 982-93.
4. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 1249-56.
5. Hamilton SR, Smith RR. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am J Clin Pathol 1987; 87: 301-12.
6. Guillem PG. How to make a Barrett esophagus: pathophysiology of columnar metaplasia of the esophagus. Dig Dis Sci 2005; 50: 415-24.
7. Chinyama CN, Marshall RE, Owen WJ, et al. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation. Histopathology 1999; 35: 517-24.
8. Regalado SP, Nambu Y, Iannettoni MD, Orringer MB, Beer DG. Abundant expression of the intestinal protein villin in Barrett's metaplasia and esophageal adenocarcinomas. Mol Carcinog 1998; 22: 182-9.
9. Paull A, Trier JS, Dalton MD, et al. The histologic spectrum of Barrett's esophagus. N Engl J Med 1976; 295: 476-80.
10. Chandrasoma PT, Lokuhetty DM, Demeester TR, et al. Definition of histopathologic changes in gastroesophageal reflux disease. Am J Surg Pathol 2000; 24: 344-51.
11. Falk GW. Barrett's esophagus. Gastroenterology 2002; 122: 1569-91.
12. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97: 1888-95.
13. Oberg S, Johansson J, Wenner J, et al. Endoscopic surveillance of columnarlined esophagus: frequency of intestinal metaplasia detection and impact of antireflux surgery. Ann Surg 2001; 234: 619-26.
14. Beck F, Erler T, Russell A, James R. Expression of Cdx-2 in the mouse embryo and placenta: possible role in patterning of the extra-embryonic membranes. Dev Dyn 1995; 204: 219-27.
15. Silberg DG, Sullivan J, Kang E, et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 2002; 122: 689-96.
16. Silberg DG, Swain GP, Suh ER, Traber PG. Cdx1 and cdx2 expression during intestinal development. Gastroenterology 2000; 119: 961-71.
17. Eda A, Osawa H, Satoh K, et al. Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. J Gastroenterol 2003; 38: 14-22.
18. Moons LM, Bax DA, Kuipers EJ, et al. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol 2004; 57: 1063-8.
19. Phillips RW, Frierson Jr HF, Moskaluk CA. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 2003; 27: 1442-7.
20. Houde M, Laprise P, Jean D, et al. Intestinal epithelial cell differentiation involves activation of p38 mitogen-activated protein kinase that regulates the homeobox transcription factor CDX2. J Biol Chem 2001; 276: 21885-94.
21. Yamamoto H, Bai YQ, Yuasa Y. Homeodomain protein CDX2 regulates gobletspecific MUC2 gene expression. Biochem Biophys Res Commun 2003; 300: 813-8.
22. Groisman GM, Amar M, Meir A. Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia. Mod Pathol 2004; 17: 1282-8.
23. Steininger H, Pfofe DA, Muller H, Haag-Sunjic G, Fratianu V. Expression of CDX2 and MUC2 in Barrett's mucosa. Pathol Res Pract 2005; 201: 573-7.
24. Corfield AP, Myerscough N, Longman R, et al. Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease. Gut 2000; 47: 589-94.
25. Bax DA, Haringsma J, Einerhand AW, et al. MUC4 is increased in high grade intraepithelial neoplasia in Barrett's oesophagus and is associated with a proapoptotic Bax to Bcl-2 ratio. J Clin Pathol 2004; 57: 1267-72.
26. Guillem P, Billeret V, Buisine MP, et al. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus. Int J Cancer 2000; 88: 856-61.
27. Warson C, Van De Bovenkamp JH, Korteland-Van Male AM, et al. Barrett's esophagus is characterized by expression of gastric-type mucins (MUC5AC, MUC6) and TFF peptides (TFF1 and TFF2), but the risk of carcinoma development may be indicated by the intestinal-type mucin, MUC2. Hum Pathol 2002; 33: 660-8.
28. Niwa T, Ikehara Y, Nakanishi H, et al. Mixed gastric- and intestinal-type metaplasia is formed by cells with dual intestinal and gastric differentiation. J Histochem Cytochem 2005; 53: 75-85.
29. Shields HM, Rosenberg SJ, Zwas FR, et al. Prospective evaluation of multilayered epithelium in Barrett's esophagus. Am J Gastroenterol 2001; 96: 3268-73.
30. Chandrasoma P. Controversies of the cardiac mucosa and Barrett's oesophagus. Histopathology 2005; 46: 361-73.
31. Hamilton SR, Yardley JH. Regnerative of cardiac type mucosa and acquisition of Barrett mucosa after esophagogastrostomy. Gastroenterology 1977; 72: 669-75.
32. Oberg S, Peters JH, DeMeester TR, et al. Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Ann Surg 1997; 226: 522-30; discussion 530-32.
33. Glickman JN, Shahsafaei A, Odze RD. Mucin core peptide expression can help differentiate Barrett's esophagus from intestinal metaplasia of the stomach. Am J Surg Pathol 2003; 27: 1357-65.
34. Chandrasoma PT, Der R, Dalton P, et al. Distribution and significance of epithelial types in columnar-lined esophagus. Am J Surg Pathol 2001; 25: 1188-93.
35. Cassaro M, Di Mario F, Leandro G, Genta RM, Rugge M. The dark side of the gastric biopsy. Hum Pathol 1999; 30: 741-4.
36. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996; 98: 2120-8.
37. Kumble S, Omary MB, Fajardo LF, Triadafilopoulos G. Multifocal heterogeneity in villin and Ep-CAM expression in Barrett's esophagus. Int J Cancer 1996; 66: 48-54.